IntelGenx Technologies Corp.
IGX
株式のランク
#28144
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
株価
$0.17446996
最終同期: 2024-06-11
時価総額
$26.97M
変化（1日）
-0.57%
変化（1年）
2.63%
国
CA
取引 IntelGenx Technologies Corp. (IGX)
カテゴリー
Healthcare
の時価総額 IntelGenx Technologies Corp.(IGX)
時価総額: $26.97M
October 2026時点で、IntelGenx Technologies Corp. の時価総額は $26.97M です。これは、当社のデータによると、IntelGenx Technologies Corp. が世界で28144th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
IntelGenx Technologies Corp. の時価総額の履歴（2007 から 2026 まで）
